Amphetamine use and its associated factors in body builders: A study from Tehran, Iran

Archives of Medical Science

Volumn 8, Issue 2, 2012, Pages 362-367

  Angoorani, Hooman ^a,b   Narenjiha, Hooman ^a,c   Tayyebi, Behnoosh ^d   Ghassabian, Akhgar ^e   Ahmadi, Gelareh ^e   Assari, Shervin ^e  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Drug Control Head Quarters (DCHQ)   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e Medicine and Health Promotion Institute (MHPI)   (Iran)

Author keywords

Amphetamines; Athletes; Bodybuilders; Sports

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANABOLIC AGENT; METHAMPHETAMINE;

ADOLESCENT; ADULT; ARTICLE; ATHLETIC PERFORMANCE; ATHLETIC TRAINER; BODY BUILDING; COST; DRUG USE; EDUCATIONAL STATUS; HEALTH SURVEY; HOUSING; HUMAN; INCOME; INTERVIEW; IRAN; MALE; MARRIAGE; MEDICAL HISTORY; NORMAL HUMAN; PHYSICAL EDUCATION; PREVALENCE; QUESTIONNAIRE; REGRESSION ANALYSIS; SECONDARY ANALYSIS; SELF ESTEEM; SUBSTANCE ABUSE;

EID: 84861477905     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.28566     Document Type: Article

References (42)

1. Peretti-Watel P, Guagliardo V, Verger P, Pruvost J, Mignon P, Obadia Y. Sporting activity and drug use: Alcohol, cigarette and cannabis use among elite student athletes. Addiction 2003; 98: 1249-56. (Pubitemid 37082818)
2. McArdle P, Wiegersma A, Gilvarry E, et al. International variations in youth drug use: the effect of individual behaviors, peer and family influences, and geographical location. Eur Addict Res 2000; 6: 163-9. (Pubitemid 32008816)
3. Pate RR, Trost SG, Levin S, Dowda M. Sports participation and health-related behaviors among US youth. Arch Pediatr Adolesc Med 2000; 154: 904-11.
4. Lorene FO, Peretti-Watel P, Grelot L. Cannabis use to enhance sportive and non-sportive performances among French sport students. Addict Behave 2005; 30: 1382-91. (Pubitemid 40973793)
5. Wagner JC. Abuse of drugs used to enhance athletic performance. Am J Hosp Pharm 1989; 46: 2059-67. (Pubitemid 20013964)
6. Challier B, Chau N, Predine R, Choquet M, Legras B. Associations of family environment and individual factors with tobacco, alcohol and illicit drug use in adolescents. Eur J Epidemiol 2000; 16: 33-42. (Pubitemid 30186763)
7. Margaria R, Aghemo P, Rovelli E. The effect of some drugs on the maximal capacity of athletic performance in man. Eur J Appl Physiol 1964; 20: 281-7.
8. The world anti doping code: The 2008 prohibited list, international standard. The world anti doping agent. Available at: http://www.wada-ama.org/ rtecontent/ document/2008-List-En.pdf. Accessed 2 May 2008.
9. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. Sports Med 1997; 24: 366-84. (Pubitemid 27527179)
10. Laties VG, Weiss B. The amphetamine margin in sports. Fed Proc 1981; 40: 2689-92. (Pubitemid 12242169)
11. Toohey JV. Non-medical drug use among intercollegiate athletes at five American universities. Bulletin on Narcotics UNODC 1978; 3: 7.
12. Alan JG. Central nervous system stimulants. Best Pract Res Clin Endocrinol Metab 2000; 14: 79-88.
13. Feizzadeh A. Ecstasy: a new substance. Social Welfare 2002; 1: 105-16.
14. Mokri A. Brief overview of the status of drug abuse in Iran. 2002. Available at: www.ams.ac.ir/AIM/0253/0253184.htm
15. Alizadeh N, Mohammadi A, Tabrizchi M. Rapid screening of methamphetamines in human serum by headspace solid-phase microextraction using a dodecylsulfate-doped polypyrrole film coupled to ion mobility spectrometry. J Chromatogr A 2008; 1183: 21-8.
16. UNODC. Epidemiology of drug use in Iran. 2009. Available athttp://www.unodc.org/iran/en/epidemiology.html. Accessed 2 May 2008.
17. Shadnia S, Esmaily H, Sasanian G, Pajoumand A, Hassanian-Moghaddam H, Abdollahi M. Pattern of acute poisoning in Tehran-Iran in 2003. Hum Exp Toxicol 2007; 26: 753-6. (Pubitemid 350157345)
18. Moghadamnia AA, Abdollahi M. An epidemiological study of acute poisonings in northern Islamic Republic of Iran. East Medit Health J 2002; 8: 88-94. (Pubitemid 39162495)
19. Daneshmandan N, Narenjiha H, Tehrani K, Assari S, Khoddami-Vishteh HR. Initiation to the first drug use among substance dependent persons in Iran. Substance Use Misuse 2011; 46: 1124-41.
20. Yassami MT, Shahmohammadi D, et al. Epidemiology of drug abuse. In I.R. Iran; Ministry of Health and Medical Education; Drug Control Headquarters 2002 (not published, In Persian).
21. Narenjiha H, Rafiey H, Baghestani AH, et al. Rapid situation assessment of drug abuse and drug dependence in Iran. DARIUS Institute 2005 (In Farsi, not published).
22. Barooni S, Mehrdad R, Akbari E. A survey of Ecstasy use among 15-25 year-olds in five areas of Tehran. Tehran University Medical Journal (TUMJ) 2007; 65: 49-54.
23. Hajiabdolbaghi M, Razani N, Karami N, et al. Insights from a survey of sexual behavior among a group of at-risk women in Tehran, Iran, 2006. AIDS Educ Prev 2007; 19: 519-30.
24. United Nations Office in Drug and Crime. 2006 World Drug Report. Geneva: United Nations 2006.
25. Iversen L. Speed, ecstasy, ritalin: the science of amphetamines. Addiction 2007; 102: 1005-7.
26. Rawson RA, Gonzales R, McCann M, Ling W. Use of methamphetamine by young people: is there reason for concern? Addiction 2007; 102: 1021-2. (Pubitemid 46918684)
27. Hao W, Xiao S, Liu T, et al. The second National Epidemiological Survey on illicit drug use at six high-prevalence areas in China: prevalence rates and use patterns. Addiction 2002; 97: 1305-15.
28. Degenhardt L, Coffey C, Moran P, Carlin JB, Patton GC. The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study. Addiction 2007; 102: 1076-84. (Pubitemid 46918664)
29. Williams P. Correlates of Ecstasy use in middle age and beyond. Drug Alcohol Rev 2005; 24: 33-8. (Pubitemid 41052844)
30. Matano RA, Wanat SF, Westrup D, Koopman C, Whitsell SD. Prevalence of alcohol and drug use in a highly educated workforce. J Behav Health Serv Res 2002; 29: 30-44. (Pubitemid 34150318)
31. Hasanian Moghadam H, Farnaghi F, Sarjami S, Zirakzadeh H. The extent of awareness among medical students of Shahid Beheshti University of Medical Sciences in the case of ecstasy. Sci J Forensic Med 2005; 11: 128-31.
32. Deas-Nesmith D, Brady KT, Withe R, Campbell S. HIV-Risk behaviors in adolescence substance abusers. J Subst Abuse Treat 1999; 16: 169-72. (Pubitemid 29066429)
33. Cuijpers P. Effective ingredients of school-based drug prevention programs. A systematic review. Addict Behav 2002; 27: 1009-23. (Pubitemid 36158761)
34. Degenhardt L, Coffey C, Carlin JB, Moran P, Patton GC. Who are the new amphetamine users? A 10-year prospective study of young Australians. Addiction 2007; 102: 1269-79. (Pubitemid 47037938)
35. Yang MS, Ko YC, Wen JK. Prevalence and related factors of substances use in female aborigines in southern Taiwan. Kaohsiung J Med Sci 1996; 12: 634-40.
36. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol 2001; 16: 599-606. (Pubitemid 34036940)
37. Kindlundh AM, Hagekull B, Isacson DG. Adolescent use of anabolic-androgenic steroids and relations to selfreports of social, personality and health aspects. Eur J Public Health 2001; 11: 322-8. (Pubitemid 32912168)
38. Lukas SE. CNS effects and abuse liability of anabolic-androgenic steroids. Ann Rev Pharmacol Toxicol 1996; 36: 333-57. (Pubitemid 26168702)
39. Bauman A, Phongsavan P. Epidemiology of substance use in adolescence: prevalence, trends and policy implications. Drug Alcohol Depend 1999; 55: 187-207. (Pubitemid 29248943)
40. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-63.
41. Harrison L. The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA Res Monogr 1997; 167: 17-36.
42. Abnet CC, Saadatian-Elahi M, Pourshams A, et al. Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev 2004; 13: 1068-70. (Pubitemid 38756720)